Carregant...
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
OBJECTIVES: To review published cost-effectiveness analyses (CEA) assessing bortezomib (BTZ) for multiple myeloma (MM) and explore possible bias affecting the cost-effectiveness of BTZ. METHODS: Literature was searched for published CEAs assessing BTZ or BTZ-containing regimens for MM from 2003 to 2...
Guardat en:
| Publicat a: | Clinicoecon Outcomes Res |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861606/ https://ncbi.nlm.nih.gov/pubmed/27217786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S104195 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|